397 related articles for article (PubMed ID: 32816190)
1. Analyzing non-sentinel axillary metastases in patients with T3-T4 cN0 early breast cancer and tumor-involved sentinel lymph nodes undergoing breast-conserving therapy or mastectomy.
Riedel F; Heil J; Feisst M; Moderow M; von Au A; Domschke C; Michel L; Schaefgen B; Golatta M; Hennigs A
Breast Cancer Res Treat; 2020 Nov; 184(2):627-636. PubMed ID: 32816190
[TBL] [Abstract][Full Text] [Related]
2. Non-sentinel axillary tumor burden applying the ACOSOG Z0011 eligibility criteria to a large routine cohort.
Riedel F; Heil J; Feißt M; Rezai M; Moderow M; Sohn C; Schütz F; Golatta M; Hennigs A
Breast Cancer Res Treat; 2019 Sep; 177(2):457-467. PubMed ID: 31236814
[TBL] [Abstract][Full Text] [Related]
3. Women Could Avoid Axillary Lymph Node Dissection by Choosing Breast-Conserving Therapy Instead of Mastectomy.
Vane MLG; Hunter-Squires J; Kim S; Smidt ML; Giuliano AE
Ann Surg Oncol; 2021 May; 28(5):2522-2528. PubMed ID: 33586070
[TBL] [Abstract][Full Text] [Related]
4. Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice?
Hennigs A; Köpke M; Feißt M; Riedel F; Rezai M; Nitz U; Moderow M; Golatta M; Sohn C; Schneeweiss A; Heil J
Breast Cancer Res Treat; 2019 Jan; 173(2):429-438. PubMed ID: 30315437
[TBL] [Abstract][Full Text] [Related]
5. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.
Giuliano AE; Ballman KV; McCall L; Beitsch PD; Brennan MB; Kelemen PR; Ollila DW; Hansen NM; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; Hunt KK; Morrow M
JAMA; 2017 Sep; 318(10):918-926. PubMed ID: 28898379
[TBL] [Abstract][Full Text] [Related]
6. A Population-Based Study of the Effects of a Regional Guideline for Completion Axillary Lymph Node Dissection on Axillary Surgery in Patients with Breast Cancer.
Tsao MW; Cornacchi SD; Hodgson N; Simunovic M; Thabane L; Cheng J; O'Brien MA; Strang B; Mukherjee SD; Lovrics PJ
Ann Surg Oncol; 2016 Oct; 23(10):3354-64. PubMed ID: 27342830
[TBL] [Abstract][Full Text] [Related]
7. Surgeon Bias in the Management of Positive Sentinel Lymph Nodes.
Mathias BJ; Sun J; Sun W; Zhou JM; Fulp WJ; Laronga C; Lee MC; Kiluk JV
Clin Breast Cancer; 2021 Feb; 21(1):74-79. PubMed ID: 32917535
[TBL] [Abstract][Full Text] [Related]
8. Evolution of the Use of Completion Axillary Lymph Node Dissection in Patients with T1/2N0M0 Breast Cancer and Tumour-Involved Sentinel Lymph Nodes Undergoing Mastectomy: A Cohort Study.
Hennigs A; Riedel F; Feißt M; Köpke M; Rezai M; Nitz U; Moderow M; Golatta M; Sohn C; Heil J
Ann Surg Oncol; 2019 Aug; 26(8):2435-2443. PubMed ID: 31049766
[TBL] [Abstract][Full Text] [Related]
9. Omitting axillary lymph node dissection after positive sentinel lymph node in the post-Z0011 era: Compliance with NCCN and ASCO clinical guidelines and Z0011 criteria in a large prospective cohort.
Costaz H; Boulle D; Bertaut A; Rouffiac M; Beltjens F; Desmoulins I; Peignaux K; Ladoire S; Causeret S; Loustalot C; Padeano MM; Vincent L; Jankowski C; Arnould L; Coutant C
Bull Cancer; 2022 Mar; 109(3):268-279. PubMed ID: 34838310
[TBL] [Abstract][Full Text] [Related]
10. Trends on Axillary Surgery in Nondistant Metastatic Breast Cancer Patients Treated Between 2011 and 2015: A Dutch Population-based Study in the ACOSOG-Z0011 and AMAROS Era.
Poodt IGM; Spronk PER; Vugts G; van Dalen T; Peeters MTFDV; Rots ML; Kuijer A; Nieuwenhuijzen GAP; Schipper RJ
Ann Surg; 2018 Dec; 268(6):1084-1090. PubMed ID: 28742702
[TBL] [Abstract][Full Text] [Related]
11. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
Sávolt Á; Péley G; Polgár C; Udvarhelyi N; Rubovszky G; Kovács E; Győrffy B; Kásler M; Mátrai Z
Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362
[TBL] [Abstract][Full Text] [Related]
12. ACOSOG Z-0011 criteria impact on axillary surgery for early breast cancer in clinical practice: Evaluation in a retrospective cohort of 1900 patients.
Dolivet E; Loaec C; Johnson A; Renaudeau C; Boiffard F; Dravet F; Brillaud Meflah V; Classe JM
Eur J Obstet Gynecol Reprod Biol; 2021 Jun; 261():41-45. PubMed ID: 33878635
[TBL] [Abstract][Full Text] [Related]
13. Impact of the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial on clinical management of the axilla in older breast cancer patients: a SEER-medicare analysis.
Caretta-Weyer H; Greenberg CG; Wilke LG; Weiss J; LoConte NK; Decker M; Steffens NM; Smith MA; Neuman HB
Ann Surg Oncol; 2013 Dec; 20(13):4145-52. PubMed ID: 23959051
[TBL] [Abstract][Full Text] [Related]
14. Potential Impact of the Z0011 Trial on the Omission of Axillary Dissection: A Retrospective Cohort Study.
Shinzato JY; Serra KP; Eugeni C; Cabello C; Cardoso-Filho C; Zeferino LC
Rev Bras Ginecol Obstet; 2021 Apr; 43(4):297-303. PubMed ID: 33784760
[TBL] [Abstract][Full Text] [Related]
15. De-escalation of axillary surgery in patients outside Z0011 criteria.
Giannakou A; Gooch J; Gergelis KR; Weiss A
Surgery; 2023 Aug; 174(2):416-418. PubMed ID: 37156648
[TBL] [Abstract][Full Text] [Related]
16. Risk factors of non-sentinel lymph node metastasis in breast cancer with 1-2 sentinel lymph node macrometastases underwent total mastectomy: a case-control study.
Huang Z; Wu Z; Zou QQ; Xie YJ; Li LH; Huang YP; Wu FM; Huang D; Pan YH; Yang JR
World J Surg Oncol; 2023 Apr; 21(1):125. PubMed ID: 37024930
[TBL] [Abstract][Full Text] [Related]
17. National Trend of Axillary Management in Clinical T3/T4 N0 Patients Having Breast Conserving Therapy.
Morris MC; Lee TC; Johnston ME; Hanseman D; Lewis JD; Shaughnessy EA; Reyna C
J Surg Res; 2020 Nov; 255():361-370. PubMed ID: 32599456
[TBL] [Abstract][Full Text] [Related]
18. Role of frozen section in sentinel lymph node biopsy for breast cancer in the era of the ACOSOG Z0011 and IBCSG 23-10 trials.
Lombardi A; Nigri G; Maggi S; Stanzani G; Vitale V; Vecchione A; Nania A; Amanti C
Surgeon; 2018 Aug; 16(4):232-236. PubMed ID: 29329752
[TBL] [Abstract][Full Text] [Related]
19. Economic implications of ACOSOG Z0011 trial application into clinical practice at the European Institute of Oncology.
Mattar D; Di Filippo A; Invento A; Radice D; Burcuta M; Bagnardi V; Magnoni F; Santomauro G; Corso G; Mazzarol G; Viale G; Sacchini V; Galimberti V; Veronesi P; Intra M
Eur J Surg Oncol; 2021 Oct; 47(10):2499-2505. PubMed ID: 34172359
[TBL] [Abstract][Full Text] [Related]
20. Application of the ACOSOG Z0011 criteria to Chinese patients with breast cancer: a prospective study.
Peng Y; Liu M; Li X; Tong F; Cao Y; Liu P; Zhou B; Liu H; Cheng L; Guo J; Xie F; Yang H; Wang S; Wang C; Chen Y; Wang S
World J Surg Oncol; 2021 Apr; 19(1):128. PubMed ID: 33879180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
